Document is current
Any future updates will be listed below
-
Authors
Bergmans, Rachel S. http://orcid.org/0000-0001-5740-6691
Wegryn-Jones, Riley http://orcid.org/0009-0006-4014-3462
Klida, Catherine
Kurtz, Vivian
Thomas, Laura http://orcid.org/0009-0003-8400-1309
Williams, David A. http://orcid.org/0000-0002-5052-4895
Clauw, Daniel J.
Kidwell, Kelley M.
Bohnert, Amy S. B.
Boehnke, Kevin F. http://orcid.org/0000-0003-3696-3979
-
Funding
Funding for this research was provided by:
State of Michigan Veteran Marijuana Research Grant Program (VMR2022-03, VMR2022-03, VMR2022-03, VMR2022-03, VMR2022-03, VMR2022-03, VMR2022-03, VMR2022-03, VMR2022-03, VMR2022-03)
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (K01ADA049219)
- License Information
-
More Information
Article History
Received: 20 March 2024
Accepted: 20 June 2024
First Online: 29 June 2024
Declarations
:
: This study was reviewed by the U.S. Food and Drug Administration (FDA), Federal Food, Drug, and Cosmetic Act for CBD and approved by the University of Michigan Institutional Review Board (IRB ID: HUM00231202).
: Not applicable.
: KFB sits on a data safety and monitoring board for an ongoing clinical trial with Vireo Health (unpaid). KFB has received speaking fees for lectures from the Medical Cannabis Research Advocacy Alliance, Providence Holy Cross Medical Center, the University of Michigan Retirees Association, and the Michigan Center of Clinical Systems Improvement.
